PURSUANT TO RULE 13a - 16 OR 15d - 16 OF


For the month of July, 2005


SkyePharma PLC

(Translation of registrant's name into English)


SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X      Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes         No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______


FOR IMMEDIATE RELEASE                                        18 July, 2005

                                 SkyePharma PLC

                       Triglide™ Launched on US Market

     Addresses Major Market Opportunity in the Treatment of Lipid Disorders

LONDON, ENGLAND, 18 July, 2005 -- SkyePharma PLC (Nasdaq: SKYE; LSE: SKP)
announces that its partner First Horizon Pharmaceutical Corporation ("First
Horizon") has launched Triglide™ (fenofibrate) and the product is now
available in pharmacies in the United States. Triglide™ is a once-daily oral
treatment for lipid disorders such as elevated cholesterol and triglycerides.
Fenofibrate not only lowers levels of total triglycerides and LDL cholesterol 
("bad cholesterol") in the bloodstream but also has the valuable property of
raising abnormally low levels of HDL cholesterol ("good cholesterol"), which is
increasingly recognized as a major cardiovascular risk factor. SkyePharma
received FDA approval for Triglide™  on 7 May 2005.

Michael Ashton, SkyePharma's Chief Executive Officer, said: "Elevated
cholesterol already affects over half of the US population and treatment
represents a major area of unmet medical need. Triglide™, our new formulation
of fenofibrate, overcomes a major drawback of an otherwise valuable medication
and fenofibrate is more effective than statins in boosting HDL levels. We see a
substantial opportunity for Triglide™.

First Horizon's 400-strong representative force focuses on cardiovascular
physicians and high-prescribing primary care practitioners and has a proven
ability to capture market share in the cardiovascular therapeutic area."

Fenofibrate is highly insoluble in water, resulting in variable uptake from the
stomach and requiring the patient to take the tablets with food. Triglide™,
the new formulation of fenofibrate developed by SkyePharma, has a comparable
absorption under fed and fasting conditions and therefore allows patients to
take the drug at any time, improving compliance and simplicity for both patients
and prescribers. Triglide™ is the first approved product utilizing
SkyePharma's proprietary IDD®-P solubilization technology.

In May 2004, SkyePharma announced that it had granted First Horizon exclusive
U.S. marketing and distribution rights for Triglide™. Under this agreement,
SkyePharma will receive up to $50 million in milestone payments, $30 million of
which are sales-based milestone payments. SkyePharma received a payment of $5
million upon signature of the agreement and a further $15 million on FDA
approval in May 2005. In addition SkyePharma will receive a royalty of 25% of
First Horizon's net sales of the product. SkyePharma will manufacture and supply
the product from its Lyon manufacturing facility. SkyePharma will also make a
contribution of up to $5 million to First Horizon's initial marketing expenses
to establish the product.

For further information please contact:

SkyePharma PLC                                              +44 207 491 1777

Michael Ashton, Chief Executive Officer
Peter Laing, Director of Corporate Communications           +44 205 491 5124

Sandra Haughton, US Investor Relations                      +1 212 753 5780

Buchanan Communications                                     +44 207 466 5000
Tim Anderson / Mark Court/ Rebecca Skye Dietrich

Notes to Editors

About SkyePharma

SkyePharma PLC develops pharmaceutical products benefiting from world-leading
drug delivery technologies that provide easier-to-use and more effective drug
formulations. There are now eleven approved products incorporating SkyePharma's
technologies in the areas of oral, injectable, inhaled and topical delivery,
supported by advanced solubilisation capabilities. For more information, visit

About lipid disorders

Lipid disorders are a group of conditions associated with excessive levels of
lipids (fatty substances) in the bloodstream. Hyperpidaemia (elevated blood
lipids) is an important risk factor in the development of atherosclerosis and
heart disease.

The major lipids in the blood are triglycerides and cholesterol, either free or
in the form of lipoproteins, molecules of fat or cholesterol linked to protein.
Types of lipoproteins include very low-density lipoproteins (VLDL), low-density
lipoproteins (LDL), and intermediate-density lipoproteins (IDL). High-density
lipoproteins (HDL), or "good cholesterol," actually reduce the risk of heart
disease and are therefore protective factors.

The treatment guidelines for hyperlipidaemia of the US National Institutes of
Health aim to reduce the incidence of heart disease. The current guidelines are
that LDL levels should be below 100 mg/dl and total cholesterol below 200 mg/dl
and HDL levels should be above 40 mg/dl. Although these guidelines are widely
accepted, it is estimated that over half of the American population have total
cholesterol above 200 mg/dl. Of these, less than half are currently treated and
of the treated group less than one third achieve the target goals.

The principal drug treatments for hyperlipidaemia are "statins" (HMG-CoA
reductase inhibitors that block endogenous synthesis of cholesterol in the
liver) and fibrates (PPAR-a agonists that increase the metabolic elimination of

References: Amer J Cardiol 2003:92:79- 81, 2001:88:265-269; Europ Heart J 2001:
22:554-772; Current-Medical-Research-and-Opinion 2004:20:1025-1033

About fenofibrate

Fenofibrate, an oral fibrate lipid lowering agent, was developed by Groupe
Fournier and first introduced internationally in 1975. In the US it was licensed
to Abbott Laboratories, which launched it in 1996 as Tricor®. Abbott's sales
of Tricor® in 2004 were US$ 778 million (a year-on-year increase of 38%).
Fenofibrate markedly reduces elevated plasma concentrations of triglycerides. It
also decreases elevated plasma concentrations of LDL and total cholesterol. At
the same time, fenofibrate increases abnormally low levels of HDL cholesterol.
The latter property is particularly important as there is growing recognition
that abnormally low levels of HDL cholesterol may represent a more important
risk factor for cardiovascular disease then elevated LDL levels. Although
statins are the most potent agents for lowering LDL levels, statins are only
modestly effective in raising HDL cholesterol levels. The mode of action of
fenofibrate is different from that of the statins and the two act
synergistically, with a significantly greater effect on lipid levels when used
together than when each is used individually. Both the current American Diabetes
Association and NICE guidelines recommend the appropriate use of fenofibrate in
combination with statins.

Fenofibrate is a prodrug of the active agent, fibric acid, and is virtually
insoluble in water. Uptake from the stomach under fasting conditions is highly
variable but uptake is substantially enhanced by food, especially by dietary

About SkyePharma's IDD®-P technology

SkyePharma has a family of proprietary technologies designed to overcome the
insolubility of many drug substances in water, which adversely affects
bioavailability. SkyePharma's Insoluble Drug Delivery-MicroParticle (IDD®-P)
technology involves preparing microparticles of active drug and then stabilizing
these with phospholipid surface modifying agents that prevent the microparticles
from reaggregating. Triglide™ tablets incorporate a novel fenofibrate
formulation developed to optimize bioavailability independent of food. In this
formulation, fenofibrate crystals have been reduced to sub-micron to micron size
particles, stabilized by phospholipid (lecithin) surface modifiers The tablets
are designed to protect and rapidly release the fenofibrate microparticles. This
expands the surface area of drug exposed to the dissolution medium and thereby
increases bioavailability.

Certain statements in this news release are forward-looking statements and are
made in reliance on the safe harbour provisions of the U.S. Private Securities
Litigation Act of 1995. Although SkyePharma believes that the expectations
reflected in these forward-looking statements are reasonable, it can give no
assurance that these expectations will materialize. Because the expectations are
subject to risks and uncertainties, actual results may vary significantly from
those expressed or implied by the forward-looking statements based upon a number
of factors, which are described in SkyePharma's 20-F and other documents on file
with the SEC. Factors that could cause differences between actual results and
those implied by the forward-looking statements contained in this news release
include, without limitation, risks related to the development of new products,
risks related to obtaining and maintaining regulatory approval for existing, new
or expanded indications of existing and new products, risks related to
SkyePharma's ability to manufacture products on a large scale or at all, risks
related to SkyePharma's and its marketing partners' ability to market products
on a large scale to maintain or expand market share in the face of changes in
customer requirements, competition and technological change, risks related to
regulatory compliance, the risk of product liability claims, risks related to
the ownership and use of intellectual property, and risks related to
SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to
revise or update any such forward-looking statement to reflect events or
circumstances after the date of this release.


     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

                                                                  SkyePharma PLC

                                                                      By: /s/ Douglas Parkhill

                                                                       Name: Douglas Parkhill
                                                                          Title: Company Secretary

Date:   July 18, 2005